康美药业
(600518)
| 流通市值：284.74亿 | | | 总市值：284.88亿 |
| 流通股本：138.22亿 | | | 总股本：138.29亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,577,397,097.25 | 1,299,297,937.56 | 5,189,137,199.65 | 3,873,558,308.67 |
| 营业收入 | 2,577,397,097.25 | 1,299,297,937.56 | 5,189,137,199.65 | 3,873,558,308.67 |
| 二、营业总成本 | 2,612,345,435.82 | 1,305,063,457.12 | 5,506,253,760.75 | 4,077,729,703.82 |
| 营业成本 | 2,091,882,757.44 | 1,063,818,220.72 | 4,422,148,257.54 | 3,325,075,721.52 |
| 税金及附加 | 22,958,613.77 | 11,753,161.29 | 67,684,265.66 | 34,368,660.08 |
| 销售费用 | 241,966,448.24 | 105,570,591 | 416,996,237.36 | 312,989,742.49 |
| 管理费用 | 237,175,089.14 | 114,208,004.44 | 542,785,988.27 | 376,004,973.56 |
| 研发费用 | 17,912,407.27 | 9,309,319.31 | 51,456,445.7 | 32,164,804.25 |
| 财务费用 | 450,119.96 | 404,160.36 | 5,182,566.22 | -2,874,198.08 |
| 其中:利息费用 | 3,128,868.69 | 1,671,114.63 | 21,387,136.02 | 8,550,479.25 |
| 其中:利息收入 | 3,366,514.32 | 1,558,858.43 | 17,227,545.66 | 12,151,440.71 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -919.26 | -1,196.03 | -1,838.54 | -395.39 |
| 加:投资收益 | 231,879.41 | 134,200.11 | 59,181,059.28 | 63,646,590.12 |
| 资产处置收益 | 286,015.92 | 255,529.68 | 39,470,945.23 | 28,206,492.87 |
| 资产减值损失(新) | -798,690.5 | -1,755,298.11 | -142,740,044.03 | -465,843.53 |
| 信用减值损失(新) | 42,034,577.77 | 10,214,764.89 | -1,130,016.33 | 55,987,468.51 |
| 其他收益 | 22,800,164.59 | 10,008,219.2 | 337,548,057.16 | 16,007,671.49 |
| 四、营业利润 | 29,604,689.36 | 13,090,700.18 | -24,788,398.33 | -40,789,411.08 |
| 加:营业外收入 | 606,841.51 | 667,556.16 | 78,995,366.14 | 66,408,066.67 |
| 减:营业外支出 | 1,689,620.99 | 1,076,256.6 | 19,556,527.93 | 6,523,211.95 |
| 五、利润总额 | 28,521,909.88 | 12,681,999.74 | 34,650,439.88 | 19,095,443.64 |
| 减:所得税费用 | 10,206,256 | 3,713,329.01 | 22,568,241.16 | 10,984,567.53 |
| 六、净利润 | 18,315,653.88 | 8,968,670.73 | 12,082,198.72 | 8,110,876.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 18,315,653.88 | 8,968,670.73 | 12,082,198.72 | 8,110,876.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 16,901,389.86 | 8,505,782.8 | 8,573,662.73 | 5,015,537.6 |
| 少数股东损益 | 1,414,264.02 | 462,887.93 | 3,508,535.99 | 3,095,338.51 |
| 扣除非经常损益后的净利润 | -3,618,595.24 | -2,572,527.89 | -533,384,001.89 | -179,522,209.77 |
| 七、每股收益 | | | | |
| 八、其他综合收益 | -30,319.91 | - | -164,285.8 | -118,139.61 |
| 归属于母公司股东的其他综合收益 | -30,319.91 | - | -164,285.8 | -118,139.61 |
| 九、综合收益总额 | 18,285,333.97 | 8,968,670.73 | 11,917,912.92 | 7,992,736.5 |
| 归属于母公司股东的综合收益总额 | 16,871,069.95 | 8,505,782.8 | 8,409,376.93 | 4,897,397.99 |
| 归属于少数股东的综合收益总额 | 1,414,264.02 | 462,887.93 | 3,508,535.99 | 3,095,338.51 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-04-19 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |